Stocks to Watch: Sinclair, TC BioPharm, Palantir Technologies, Dell Technologies, Erie Indemnity

Dow Jones2024-09-06

By Connor Hart

Sinclair ousted Ken Solomon, longtime chairman and chief executive of the Tennis Channel, The Wall Street Journal reported. The shake-up won't affect Sinclair's plans to sell the channel, according to people familiar with the matter. Sinclair executives cited Solomon's involvement in activities not related to the Tennis Channel, such as his role as a board member and an adviser for Dr. Phil McGraw's company, Merit Street Media, as a growing distraction. Shares rise 8.3%, to $14.29, in after-hours trading.

Palantir Technologies, Dell Technologies and Erie Indemnity were added to S&P 500 following Friday's market close. Palantir will replace American Airlines, Dell will replace Etsy and Erie will replace Bio-Rad Laboratories in the index before the start of trading on Sept. 23. In after-hours trading, shares of Palantir rise 7.5%, to $32.62; shares of Dell rise 5.5%, to $107.60; and shares of Erie rise 2.9%, to $521.10.

TC BioPharm after the bell said it intends to begin preclinical studies for its lead therapeutic, which uses activated and expanded gamma delta T cells as a treatment for monkeypox. The biotechnology company said it expects to partner with an infectious disease center or university to conduct its studies. Shares fall 3.7%, to $7.56, in post-market trading.

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

September 06, 2024 18:58 ET (22:58 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment